Literature DB >> 29933088

Time to Resolution of Symptoms After Suboccipital Decompression with Duraplasty in Children with Chiari Malformation Type I.

Eveline Teresa Hidalgo1, Yosef Dastagirzada2, Cordelia Orillac2, Svetlana Kvint2, Emily North2, Ramona Bledea2, Michelle W McQuinn2, Gabriel Redel-Traub2, Crystalann Rodriguez2, Jeffrey H Wisoff2.   

Abstract

BACKGROUND: Duraplasty is a technique successfully used to treat Chiari malformation type I (CM-I). This study describes the timely manner of clinical outcomes and the postoperative course after craniectomy and duraplasty for the treatment of symptomatic CM-I in children.
METHODS: A retrospective chart review was performed in 105 consecutive children who underwent surgical decompression of symptomatic CM-I with dural opening by a single surgeon between 1999 and 2015.
RESULTS: In 16 of 28 children (57%) with typical Valsalva-related/tussive and mixed headaches, the symptoms resolved before discharge; by 6 months, all children were headache-free. Two of 28 children (7%) had recurrent headaches 9 months after surgery. Among the 78 children with syrinx, syrinx resolved or decreased in 68 (87%), recurred in 8 (10%), and was stable in 2 children (3%). Syrinx was resolved or decreased by 3 months in 51 children (65%) and by 6 months in 62 children (79%). Complications included aseptic meningitis requiring reoperation in 3 children (3%) and infection in one child (1%). Twelve children underwent reoperation, none within the first 30 days. No child had a major morbidity or mortality.
CONCLUSIONS: In carefully selected children with CM-I, a high success rate can be achieved with suboccipital decompression and duraplasty. Valsalva-related/tussive headaches resolved by the time of discharge from the hospital in the majority of children, and syrinx resolved or decreased in two-thirds of the children by 3 months. By 6 months, headaches were resolved in all cases, and syrinx was resolved or decreased in 79% of cases.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chiari malformation type I; Duraplasty; Headache; Outcome; Suboccipital decompression; Syringomyelia

Mesh:

Year:  2018        PMID: 29933088     DOI: 10.1016/j.wneu.2018.06.073

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  6 in total

1.  Management of Chiari malformations: opinions from different centers-a review.

Authors:  David S Hersh; Mari L Groves; Frederick A Boop
Journal:  Childs Nerv Syst       Date:  2019-05-24       Impact factor: 1.475

2.  Outcomes and complications for individual neurosurgeons for the treatment of Chiari I malformation at a children's hospital.

Authors:  Tasha-Kay Walker-Palmer; D Douglas Cochrane; Ashutosh Singhal; Paul Steinbok
Journal:  Childs Nerv Syst       Date:  2019-05-24       Impact factor: 1.475

3.  Bony decompression vs duraplasty for Chiari I malformation: does the eternal dilemma matter?

Authors:  Luca Massimi; P Frassanito; F Bianchi; G Tamburrini; M Caldarelli
Journal:  Childs Nerv Syst       Date:  2019-06-18       Impact factor: 1.475

Review 4.  Risk of meningitis after posterior fossa decompression with duraplasty using different graft types in patients with Chiari malformation type I and syringomyelia: a systematic review and meta-analysis.

Authors:  Omar F Jbarah; Bahaa I Aburayya; Ayman R Shatnawi; Mohab A Alkhasoneh; Ahmad A Toubasi; Sondos M Alharahsheh; Saleem K Nukho; Asil S Nassar; Mohammad A Jamous
Journal:  Neurosurg Rev       Date:  2022-10-01       Impact factor: 2.800

5.  Timing to surgery of Chiari malformation type 1 affects complication types: An analysis of 13,812 patients.

Authors:  Sara Naessig; Bhaveen H Kapadia; Ashok Para; Waleed Ahmad; Katherine Pierce; Burhan Janjua; Shaleen Vira; Bassel Diebo; Daniel Sciubba; Peter Gust Passias
Journal:  J Craniovertebr Junction Spine       Date:  2020-08-14

6.  Management of Chiari type I malformation: a retrospective analysis of a series of 91 children treated surgically.

Authors:  Théo Broussolle; Pierre Aurélien Beuriat; Alexandru Szathmari; Christophe Rousselle; Federico Di Rocco; Carmine Mottolese
Journal:  Acta Neurochir (Wien)       Date:  2021-06-23       Impact factor: 2.216

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.